GLP-1 medications act on one natural hormone that helps control appetite and blood sugar. GLP-1 + GIP treatments activate two related hormones, offering a broader effect on appetite, glucose balance, and overall metabolic function.
GLP-1 + GIP treatments may lead to steadier and faster metabolic improvements in some patients because they act through two complementary hormone pathways. Individual response varies, and both require consistency and medical supervision.
Both are considered safe when prescribed and monitored by licensed clinicians. Each carries potential side effects such as nausea, constipation, and digestive discomfort, which usually lessen over time with proper dose adjustment.
People who have not achieved their desired metabolic stability or appetite control with GLP-1 therapy alone may benefit from the dual-action approach under provider guidance.
Yes. Licensed clinicians evaluate each patient to determine whether GLP-1 or GLP-1 + GIP treatment is the most appropriate based on medical history, goals, and current health status.
Yes. Both are typically administered once weekly via subcutaneous injection. Your clinician will provide detailed instructions for safe, at-home use.
They should not be used together or combined with other GLP-1–based therapies. Your clinician will review all current prescriptions to avoid interactions and adjust dosing safely.
Both options are available through Invigor Medical’s telehealth platform with transparent pricing and ongoing medical oversight. Your clinician will recommend the most clinically appropriate and cost-effective choice for your situation.
Important Medication Info:
FDA-approved medications such as Mounjaro® and Zepbound™ are proprietary to Eli Lilly and Company™, while Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™. This website is not affiliated with, endorsed by, or associated with these companies or their products.
Invigor Medical does not supply FDA-approved branded medications. Instead, compounded GLP-1 + GIP alternatives may be prescribed when clinically appropriate and legally permissible. These compounded medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available options are unsuitable for an individual’s medical needs, but they have not been evaluated by the FDA to confirm safety or efficacy for any specific use.
Important Safety Information for GLP-1 + GIP Treatments
Compounded medications are legally prescribed under federal law but are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The GLP-1 + GIP treatment available through Invigor Medical is prescribed following an individualized medical evaluation by a licensed clinician.
WARNING: Risk of Thyroid C-Cell Tumors
In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether these effects occur in humans. Inform your healthcare provider if you experience neck swelling, hoarseness, difficulty swallowing, or shortness of breath. GLP-1 + GIP treatments should not be used by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use GLP-1 + GIP treatments if:
Warnings and Precautions:
Pregnancy and Reproductive Health:
GLP-1 + GIP medications may cause harm to a fetus and should not be used during pregnancy or by individuals planning to become pregnant. Discontinue at least two months before a planned pregnancy.
Common Side Effects:
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, fatigue, and headache are the most commonly reported side effects.
Drug Interactions:
GLP-1 + GIP treatments may slow gastric emptying and alter the absorption of oral medications. Consult your healthcare provider for guidance on timing and dosage adjustments.